Literature DB >> 32897828

MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype.

David M Gershenson1, Charlie Gourley2, James Paul3.   

Abstract

Entities:  

Year:  2020        PMID： 32897828     DOI： 10.1200/JCO.20.02190

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation.

Authors:  Bárbara Lima; Miguel Henriques Abreu; Susana Sousa; Carla Bartosch; Deolinda Pereira
Journal:  Gynecol Oncol Rep       Date:  2022-02-23

Review 2.  Traditional Systemic Treatment Options in Advanced Low-Grade Serous Ovarian Cancer after Successful Cytoreduction: A Systematic Review and Meta-Analysis.

Authors:  Rosa Montero-Macías; Pascal Rigolet; Elie Mikhael; Jonathan Krell; Vincent Villefranque; Fabrice Lecuru; Christina Fotopoulou
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

3.  Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer.

Authors:  Yichao Li; Sushil K Jaiswal; Rupleen Kaur; Dana Alsaadi; Xiaoyu Liang; Frank Drews; Julie A DeLoia; Thomas Krivak; Hanna M Petrykowska; Valer Gotea; Lonnie Welch; Laura Elnitski
Journal:  BMC Cancer       Date:  2021-07-03       Impact factor: 4.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.